NASDAQ$SGRY
Surgery Partners Inc · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
Surgery Partners reported Q4 2024 revenue of $864.4M with a net loss of $108.5M and adjusted EBITDA of $163.8M.
Revenues increased 17.5% to $864.4 million with same-facility revenue up 5.6%. Net loss attributable to Surgery Partners was $108.5 million on a deferred tax valuation allowance; adjusted EBITDA rose 15.1% to $163.8 million.
- Q4 revenue $864.4M (+17.5% YoY).
- Same-facility revenue +5.6%.
- Adjusted EBITDA $163.8M (+15.1% YoY).
- FY25 revenue outlook $3.30B–$3.45B.
Headline financials
Revenue & EPS history
Surgery Partners · Revenue · Quarterly
$864M
Forward guidance
Outlook emphasizes clinical milestones, liquidity runway, and operating expense discipline.
Tailwinds
- Pipeline progress and partnership economics.
- Cash supports near-term operating plans.
Headwinds
- Operating losses until commercial scale.
- Financing and trial outcomes affect funding costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+1.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
-1.2%
Avg return
30 days after
57%
28 / 49 earnings
Positive
+26.2%
Q2 2020
Best reaction
-35.9%
Q2 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.4% | +1.7% | -3.7% | |
| Q4 2025 | -12.5% | -15.9% | -23.3% | |
| Q3 2025 | -25.4% | -28.9% | -23.1% | |
| Q1 2025 | +5.1% | +8.0% | +4.6% | |
| Q4 2024 | -0.3% | -0.1% | -2.2% | |
| Q3 2024 | -18.8% | -27.0% | -35.6% | |
| Q2 2024 | -0.4% | +3.6% | +7.9% | |
| Q1 2024 | +6.1% | +3.9% | +1.3% | |
| Q4 2023 | -3.6% | -5.6% | -9.4% | |
| Q3 2023 | +10.4% | +5.5% | +30.9% | |
| Q2 2023 | -4.0% | -4.6% | -6.1% | |
| Q1 2023 | -6.3% | -11.2% | -5.5% | |
| Q4 2022 | -1.8% | -0.5% | +3.0% | |
| Q3 2022 | -11.7% | +17.9% | +5.7% | |
| Q2 2022 | -2.5% | -1.7% | -30.6% | |
| Q1 2022 | +11.2% | +0.8% | -21.3% | |
| Q4 2021 | +4.7% | +1.6% | +6.4% | |
| Q3 2021 | +17.7% | +22.8% | +13.0% | |
| Q2 2021 | -13.1% | -15.2% | -8.6% | |
| Q1 2021 | +5.2% | +2.1% | +22.6% | |
| Q4 2020 | +3.4% | +7.2% | +11.9% | |
| Q3 2020 | -5.8% | +0.7% | +14.0% | |
| Q2 2020 | +26.2% | +26.1% | +25.3% | |
| Q1 2020 | +1.2% | -9.7% | +34.5% | |
| Q4 2019 | -29.6% | -34.8% | -68.6% | |
| Q3 2019 | +22.4% | +35.2% | +60.8% | |
| Q2 2019 | +7.9% | -4.1% | +0.3% | |
| Q1 2019 | -5.1% | -6.7% | -19.9% | |
| Q4 2018 | +5.4% | +9.0% | -9.6% | |
| Q3 2018 | +6.2% | +0.7% | -6.7% | |
| Q2 2018 | +13.0% | +10.8% | -2.2% | |
| Q1 2018 | +7.0% | +16.1% | -12.9% | |
| Q4 2017 | +0.9% | +6.0% | +8.2% | |
| Q3 2017 | +18.5% | +8.0% | +14.8% | |
| Q2 2017 | -35.9% | -41.4% | -47.5% | |
| Q1 2017 | +17.4% | +21.0% | +22.1% | |
| Q4 2016 | -10.2% | -6.9% | -9.3% | |
| Q3 2016 | -8.4% | -2.8% | -7.8% | |
| Q2 2016 | +1.0% | +10.3% | +19.2% | |
| Q1 2015 | -2.7% | — | — | |
| Q1 2016 | -7.6% | — | — | |
| Q2 2015 | +13.1% | — | — | |
| Q1 2014 | +13.1% | — | — | |
| Q4 2013 | +13.1% | — | — | |
| Q2 2014 | +13.1% | — | — | |
| Q4 2015 | +17.1% | — | — | |
| Q3 2014 | +2.8% | — | — | |
| Q4 2014 | +2.8% | — | — | |
| Q3 2015 | -0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro